Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Ventyx Biosciences's VTX-2735?
VTX-2735 is a small molecule commercialized by Ventyx Biosciences, with a leading Phase II program in Familial Cold Autoinflammatory Syndrome...
VTX-3232 by Ventyx Biosciences for Parkinson's Disease: Likelihood of Approval
VTX-3232 is under clinical development by Ventyx Biosciences and currently in Phase I for Parkinson's Disease. According to GlobalData, Phase...
VTX-3232 by Ventyx Biosciences for Neuroinflammation: Likelihood of Approval
VTX-3232 is under clinical development by Ventyx Biosciences and currently in Phase I for Neuroinflammation. According to GlobalData, Phase I...
VTX-2735 by Ventyx Biosciences for Familial Cold Autoinflammatory Syndrome (Familial Cold Urticaria): Likelihood of Approval
VTX-2735 is under clinical development by Ventyx Biosciences and currently in Phase II for Familial Cold Autoinflammatory Syndrome (Familial Cold...
VTX-958 by Ventyx Biosciences for Crohn's Disease (Regional Enteritis): Likelihood of Approval
VTX-958 is under clinical development by Ventyx Biosciences and currently in Phase II for Crohn's Disease (Regional Enteritis). According to...
VTX-958 by Ventyx Biosciences for Systemic Lupus Erythematosus: Likelihood of Approval
VTX-958 is under clinical development by Ventyx Biosciences and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
VTX-3232 by Ventyx Biosciences for Multiple Sclerosis: Likelihood of Approval
VTX-3232 is under clinical development by Ventyx Biosciences and currently in Phase I for Multiple Sclerosis. According to GlobalData, Phase...
Tamuzimod by Ventyx Biosciences for Ulcerative Colitis: Likelihood of Approval
Tamuzimod is under clinical development by Ventyx Biosciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase...